Company profile
Lantern Pharma Inc.
NASDAQ:LTRNBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Zirdafulven | phase1_2 | — | 1 | active |
| Zirdafulven, (S)- | phase1 | — | 1 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05456256 | phase2 | recruiting | 2023-03-01 | 2026-12-01 | Lantern Pharma Inc. | A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma |
| NCT06132503 | phase1 | recruiting | 2023-01-03 | 2028-11-30 | Lantern Pharma Inc. | Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors |
| NCT05933265 | phase1_2 | active_not_recruiting | 2023-06-09 | 2026-07-28 | Lantern Pharma Inc. | Study of LP-184 in Patients With Advanced Solid Tumors |
FDA applications (0)
No records yet.